CALC — Calcimedica Share Price
0.000.00%
Last trade - 00:00- $44.40m
- $18.69m
- 14
- 12
- 93
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.33 | ||
| Price to Tang. Book | 3.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -94.11% | ||
| Return on Equity | -76.09% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).
Directors
- Christy Shaffer NEC (63)
- Frederic Guerard PRE (48)
- Robert Breuil CFO (59)
- Daniel Salain CTO (53)
- Parisa Zamiri OTH (56)
- Christina Ackermann IND (56)
- Eric Bjerkholt IND (61)
- Gerald Cagle IND (76)
- Julie Eastland IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 19th, 2015
- Public Since
- September 25th, 2020
- No. of Shareholders
- 92
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,749,065
- Address
- 505 Coast Boulevard South, Suite 307, LA JOLLA, 92037
- Web
- https://calcimedica.com/
- Phone
- +1 8589525500
- Contact
- Sarah Sutton
- Auditors
- Ernst & Young LLP
Upcoming Events for CALC
Q3 2024 CalciMedica Inc Earnings Release
Similar to CALC
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Calcimedica share price?
As of Today at 19:46 UTC, shares in Calcimedica are trading at $5.35. This share price information is delayed by 15 minutes.
How has the Calcimedica share price performed this year?
Shares in Calcimedica last closed at $5.35 and the price had moved by +50.7% over the past 365 days. In terms of relative price strength the Calcimedica share price has outperformed the S&P500 Index by +19.92% over the past year.
What are the analyst and broker recommendations for Calcimedica?
The overall consensus recommendation for Calcimedica is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Calcimedica dividend yield?
Calcimedica does not currently pay a dividend.
Does Calcimedica pay a dividend?
Calcimedica does not currently pay a dividend.
When does Calcimedica next pay dividends?
Calcimedica does not currently pay a dividend.
How do I buy Calcimedica shares?
To buy shares in Calcimedica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Calcimedica?
As of the previous close price of $5.35, shares in Calcimedica had a market capitalisation of $57.51m.
Where are Calcimedica shares listed?
Here are the trading details for Calcimedica:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CALC
What kind of share is Calcimedica?
Based on an overall assessment of its quality, value and momentum Calcimedica is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Calcimedica share price forecast for 2024?
The analyst consensus target price for shares in Calcimedica is $16.69. That is 211.96% above the last closing price of $5.35.
Analysts covering Calcimedica currently have a consensus Earnings Per Share (EPS) forecast of -$1.61 for the next financial year.
What is the trend in the Calcimedica share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Calcimedica. Over the past six months, its share price has outperformed the S&P500 Index by +53.27%.
As of the last closing price of $5.35, shares in Calcimedica were trading +32.57% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Calcimedica PE Ratio?
The Calcimedica PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Calcimedica?
Calcimedica's management team is headed by:
- Christy Shaffer - NEC
- Frederic Guerard - PRE
- Robert Breuil - CFO
- Daniel Salain - CTO
- Parisa Zamiri - OTH
- Christina Ackermann - IND
- Eric Bjerkholt - IND
- Gerald Cagle - IND
- Julie Eastland - IND